Observational study finds higher clomiphene doses increase miscarriage risk without improving live birth odds — Evidence Review
Published in BMJ Open, by researchers from Adelaide University, Boston University, Centers for Disease Control and Prevention
Researched by
— the AI search engine for science
Table of Contents
A large U.S. study finds that women receiving higher cumulative doses of the fertility drug clomiphene citrate face rising risks of miscarriage and multiple pregnancy, without improved odds of a live birth. Most prior research is broadly consistent with these findings, though some earlier studies reported limited or unclear evidence regarding miscarriage risk at varying doses; the new study from BMJ Open provides more robust evidence.
- Previous systematic reviews and cohort studies have shown clomiphene citrate is effective for inducing ovulation and increasing pregnancy rates, but the effects on miscarriage and multiple pregnancy rates have been poorly reported or remained uncertain, especially as cumulative doses rise 1 2.
- Some studies suggested that prolonged or higher-dose clomiphene treatment may increase ovarian hyperstimulation and multiple pregnancy risk, and experimental animal research has linked higher clomiphene exposure to adverse reproductive outcomes 2 11.
- Observational data also indicate a possible dose-dependent increase in certain cancer risks and adverse pregnancy outcomes, supporting the new findings that risk rises with greater cumulative exposure 12.
Study Overview and Key Findings
Fertility treatments with clomiphene citrate have been a mainstay for decades, especially for women who do not ovulate regularly. While the drug is widely prescribed and generally regarded as safe at recommended dosages, clinical decision-making around repeated cycles or escalating doses is often based on limited evidence. Recent emphasis on achieving healthy, singleton births—and avoiding unnecessary risks—makes understanding cumulative drug effects especially timely.
The new study analyzed over 21,000 IVF embryo transfer cycles in the United States, focusing on how increasing cumulative doses of clomiphene citrate affected miscarriage risk, multiple births, and live birth rates. Unlike smaller or older studies, this analysis provides a large-scale, contemporary perspective on the tradeoffs of extended clomiphene use.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Adelaide University, Boston University, Centers for Disease Control and Prevention |
| Journal Name | BMJ Open |
| Authors | Sheree Boulet, Yujia Zhang, Dmitry Kissin, Michael Davies |
| Population | Women undergoing IVF embryo transfer cycles |
| Sample Size | n=21,004 |
| Methods | Observational Study |
| Outcome | Miscarriage risk, multiple births, live birth odds |
| Results | Higher doses of clomiphene increased miscarriage risk without improving live birth odds. |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus research database (which includes over 200 million papers) using targeted queries. The following search queries were used:
The most relevant themes and findings from related studies are summarized below:
| Topic | Key Findings |
|---|---|
| What are the risks of miscarriage and multiple pregnancy with clomiphene use? | - Clomiphene increases ovulation and pregnancy rates, but effects on miscarriage and multiple pregnancy rates are unclear or poorly reported in most trials 1. - Prolonged or high-dose clomiphene use is associated with increased risk of multiple pregnancy and possibly higher miscarriage rates, especially in specific subgroups 2 3 5. |
| How does cumulative or high-dose clomiphene impact live birth and adverse outcomes? | - Higher cumulative doses may not improve live birth rates and can increase risk of ovarian hyperstimulation, multiple pregnancy, and potentially cancer 2 12. - Animal studies show dose-dependent adverse effects on pregnancy success and fetal development 11. |
| How do patient characteristics and treatment protocols influence outcomes? | - Factors such as age, BMI, ovarian morphology, and treatment history significantly affect live birth and miscarriage rates after IVF and clomiphene cycles 2 3 6 7 9 10. - Personalized approaches and adherence to recommended treatment cycles are important to optimize outcomes and minimize risk 2 7 10. |
| What is the evidence for long-term or rare adverse events with clomiphene? | - Some studies report a possible association between higher or prolonged clomiphene exposure and increased uterine or ovarian cancer risk, particularly in nulligravid or obese women 12. - Evidence for long-term safety is limited, and rare outcomes require larger, long-term studies for clarification 12 14. |
What are the risks of miscarriage and multiple pregnancy with clomiphene use?
The literature consistently notes that clomiphene citrate effectively induces ovulation and increases pregnancy rates, but its impact on miscarriage and multiple pregnancy rates has often been insufficiently studied or reported. Some older studies and systematic reviews found unclear links between clomiphene and miscarriage, while others observed increased risk of multiple pregnancy, particularly with higher or prolonged dosing. The new study's findings of increased miscarriage and multiple birth risk with higher cumulative doses align with these observations, but provide more robust, dose-specific data.
- Systematic reviews have found that while clomiphene increases pregnancy rates, data on miscarriage and multiple pregnancy outcomes are limited or poorly reported 1.
- Prolonged or higher-dose treatment may elevate the risk of ovarian hyperstimulation and multiple pregnancy, as noted in clinical and cohort studies 2 5.
- Women with polycystic ovaries undergoing IVF with clomiphene had higher miscarriage rates compared to other protocols, suggesting specific subgroups may be more vulnerable 3.
- The new study adds large-scale, contemporary evidence for a dose-dependent increase in these risks.
How does cumulative or high-dose clomiphene impact live birth and adverse outcomes?
Across the literature, several studies have raised concerns that increasing cumulative doses of clomiphene do not necessarily translate to higher live birth rates, but may elevate various risks. This includes ovarian hyperstimulation, multiple pregnancy, and even rare but serious adverse events like cancer. Experimental animal models have also shown dose-dependent negative effects on reproductive outcomes.
- High cumulative clomiphene exposure has been associated with greater risk of ovarian hyperstimulation and multiple pregnancies, without corresponding improvements in live birth rates 2.
- Animal studies demonstrate that higher doses can reduce successful pregnancy rates, increase fetal loss, and cause developmental abnormalities 11.
- Epidemiologic studies suggest a possible link between higher cumulative doses and increased uterine cancer risk, particularly among certain patient groups 12.
- The new study reinforces the need for caution with escalating or repeated clomiphene treatment.
How do patient characteristics and treatment protocols influence outcomes?
Patient-level factors and treatment decisions substantially influence outcomes with fertility drugs and IVF. Age, BMI, ovarian morphology, and previous treatment history all play important roles in predicting live birth and miscarriage odds. The literature supports a trend toward more personalized treatment approaches and limiting unnecessary exposure to fertility drugs.
- Increased BMI is a consistent predictor of reduced response to clomiphene and poorer outcomes, highlighting the importance of individual patient assessment 2.
- Ovarian morphology (e.g., presence of polycystic ovaries) and specific IVF protocols impact miscarriage rates and may alter the risk-benefit profile for clomiphene 3 6 9.
- Cumulative conception rates plateau after 6–12 cycles, and guidelines recommend limiting clomiphene use to about six cycles to avoid unnecessary risk 2 10.
- The new study’s findings support the need for careful, individualized dosing and strict adherence to recommended treatment durations.
What is the evidence for long-term or rare adverse events with clomiphene?
While clomiphene has a long track record of use, evidence about rare or long-term adverse effects remains limited. Some cohort studies have found possible associations between higher or prolonged clomiphene exposure and uterine or ovarian cancer, particularly in high-risk subgroups. However, these findings are often based on small numbers of cases, and more research is needed.
- Observational research links long-term or high-dose clomiphene use to increased risk of uterine cancer, especially among nulligravid and obese women 12.
- Animal and mechanistic studies indicate that clomiphene can alter reproductive tissue physiology and may have lasting effects at higher exposures 11 13 15.
- The current study’s findings about increased risk at higher cumulative doses highlight the importance of monitoring for rare but serious adverse events, and the need for large, long-term studies.
- Existing guidelines already recommend limiting clomiphene cycles and dose escalation, but adherence in real-world practice varies 2 12 14.
Future Research Questions
While the new study advances understanding of cumulative clomiphene risk, several important questions remain unanswered. Further research is needed to clarify the mechanisms underlying increased miscarriage and stillbirth risk at higher doses, to identify which patient subgroups may be most vulnerable, and to assess the long-term safety of clomiphene and alternative fertility drugs. Large-scale, prospective studies and personalized medicine approaches could help optimize treatment while minimizing unnecessary risk.
| Research Question | Relevance |
|---|---|
| What are the mechanisms by which high cumulative clomiphene doses increase miscarriage risk? | Understanding the biological pathways could enable safer drug protocols and mitigation strategies; mechanistic insights are lacking in both human and animal studies 11. |
| Which patient subgroups are most susceptible to adverse effects from clomiphene treatment? | Evidence suggests higher risk among women with specific characteristics (e.g., polycystic ovaries, high BMI, nulligravid) but more targeted studies are needed 2 3 12. |
| Does personalized or lower-dose clomiphene dosing improve live birth rates and reduce adverse events? | Current guidelines recommend individualized dosing, but robust evidence for optimal strategies is limited; further trials are warranted 2 7 10. |
| How do newer fertility drugs compare to clomiphene in terms of efficacy and safety? | Some clinicians are moving away from clomiphene, but comparative studies of alternative ovulation-inducing medications remain limited 14. |
| What are the long-term health outcomes for women and offspring after high-dose or repeated clomiphene exposure? | Long-term risks such as cancer and developmental outcomes remain uncertain, especially for high-dose or repeated exposures; large cohort studies are needed 12 14. |